

22nd April 2026

BSE Limited

Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai - 400 001
Scrip Code: BSE – AJANTPHARM 532331

National Stock Exchange of India

Exchange Plaza, 5th Floor, Plot No. C/1,
G block, Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051
Scrip Code: NSE AJANTPHARM EQ

Sub: Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations')

Dear Sir / Madam,

This is to inform you that the US FDA has concluded an inspection at our manufacturing facility at Paithan, in Maharashtra. The Inspection was conducted from April 13th, 2026, to April 21, 2026, and closed with the issuance of Form-483 with 5 (five) observations.

The Company will respond to the US FDA within the stipulated timeline.

This is for your information and record.

Yours faithfully,
For **Ajanta Pharma Limited**

Gaurang Shah
Sr. VP – Legal & Company Secretary